Bayer plc

Bayer House, Strawberry Hill, Newbury, Berkshire, RG14 1JA
Telephone: +44 (0)1635 563 000
Fax: +44 (0)1635 563 393
WWW: http://www.bayer.co.uk

Summary of Product Characteristics last updated on the eMC: 13/05/2011
SPC Femodette

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 13/05/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 6. 6 - Instructions for use, handling and disposal
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   19-Jan-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

The key change is:

Section 6.6

 

has been updated in line with EC Guideline and now states 'No special requirements

 

Updated on 30/06/2009 and displayed until 13/05/2011
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   06-Mar-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



The key changes to the SmPC are:

 

·       Section 6.5 (Nature and contents of container) – the text has been updated from:

 

     'The blister packs consist of hard tempered aluminium foil of thickness 20µm and transparent PVC film of thickness 250µm. 

           

            Presentation

            Cartons containing 1 or 3 blister memo-packs

            Each memo-pack contains 21 tablets'.

 

to:


           
'Primary containers:

The blister packs consist of hard tempered aluminium foil of thickness 20m and transparent PVC film of thickness 250m.

 

Presentation:

Blister calendar pack contaiing 21 tablets.'

 

·       Section 9 (Date of first authorisation / Renewal of the authorisation) has been updated to reflect the Renewal approval date of 06 March 2009. 

 

·       Section 10 (Date of revision of the text) has been updated to reflect the Renewal approval date of 06 March 2009. 

 

Updated on 28/05/2008 and displayed until 30/06/2009
Reasons for adding or updating:
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-May-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



All updates are due to change of ownership, from Schering Healthcare Ltd to Bayer Plc effective from 1 May 2008

Section 7: MAH now Bayer plc
Section 8: Licence number is now PL 00010/ 0531
Section 9: Date of first authorisation is now 1 May 2008
Section 10: Revision date is now 1 May 2008 

Updated on 08/01/2002 and displayed until 28/05/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
Updated on 25/07/2001 and displayed until 08/01/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 21/08/2000 and displayed until 25/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   ethinylestradiol
   gestodene